←Back to Expert Scholars
Translational Medicine / 转化医学Milestone IO Approvals
Patrick Hwu
MD
🏢Moffitt Cancer Center🌐USA
President and CEO
100
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Patrick Hwu has been a leader in tumor infiltrating lymphocyte (TIL) therapy development, contributing to studies leading to the 2024 FDA approval of lifileucel (Amtagvi) for advanced melanoma. He serves as president and CEO of Moffitt Cancer Center and previously led MD Anderson melanoma research.
Share:
🧪Research Fields 研究领域
TIL therapy
adoptive cell therapy
melanoma immunotherapy
lifileucel approval
cellular IO
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Patrick Hwu 的研究动态
Follow Patrick Hwu's research updates
留下邮箱，当我们发布与 Patrick Hwu（Moffitt Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment